Physiological modeling of formulated and crystalline 3,3′ -diindolylmethane pharmacokinetics following oral administration in mice

Drug Metabolism and Disposition

Volumn 32, Issue 6, 2004, Pages 632-638

  Anderton, Mark J ^a   Manson, Margaret M ^a   Verschoyle, Richard ^a   Gescher, Andreas ^a   Steward, William P ^a   Williams, Marion L ^a,b   Mager, Donald E ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3' DIINDOLYLMETHANE; INDOLE DERIVATIVE; INDOLPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE KIDNEY FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG FORMULATION; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MODEL; MOUSE; NONHUMAN; PHARMACOKINETICS; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTICARCINOGENIC AGENTS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; FEMALE; INDOLES; MICE; MICE, INBRED STRAINS; MODELS, BIOLOGICAL; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 2442672870     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.6.632     Document Type: Article

References (39)

1. Anderton MJ, Jukes R, Lamb JH, Manson MM, Gescher A, Steward WP, and Williams ML (2003a) Liquid chromatographic assay for the simultaneous determination of indole-3-carbinol and its acid condensation products in plasma. J Chromatogr Biomed Appl 787:281-291.
2. Anderton MJ, Manson MM, Verschoyle RD, Gescher A, Steward WP, and Williams ML (2003b) Pharmacokinetics and tissue disposition of indole-3-carbinol and 3,3-diindolylmethane after oral administration to mice (Abstract). Proc Am Assoc Cancer Res 44:2887.
3. Arneson DW, Hurwitz A, McMahon LM, and Robaugh D (1999) Presence of 3,3′-diindolylmethane in human plasma after oral administration of indole-3-carbinol (Abstract). Proc Am Assoc Cancer Res 40:2833.
4. Bell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, Mayeaux EJ, Tucker A, Turbat-Herrera EA, and Mathis JM (2000) Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 78:123-129.
5. Blakey GE, Nestorov IA, Arundel PA, Aarons LJ, and Rowland M (1997) Quantitative structure pharmacokinetics relationships: 1. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat. J Pharmacokinet Biopharm 25:277-312.
6. Bonnesen C, Eggleston IM, and Hayes JD (2001) Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. Cancer Res 61:6120-6130.
7. Bradfield CA and Bjeldanes LF (1987) Structure-activity relationships of dietary indoles: a proposed mechanism of action as modifiers of xenobiotic metabolism. J Toxicol Environ Health 21:311-323.
8. Bradlow HL, Michnovicz JJ, Halper M, Miller DG, Wong GY, and Osborne MP (1994) Long-term responses of women to indole-3-carbinol or a high fiber diet. Cancer Epidemiol Biomark Prev 3:591-595.
9. Bradlow HL, Michnovicz JJ, Telang NT, and Osborne MP (1991) Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis (Oxf) 12:1571-1574.
10. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, and Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407-484.
11. Chen DZ, Qi M, Auborn KJ, and Carter TH (2001) Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium. J Nutr 131:3294-3302.
12. Chen I, McDougal A, Wang F, and Safe S (1998) Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis (Oxf) 19:1631-1639.
13. D'Argenio DZ and Schumitzky A (1997) ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, Los Angeles.
14. Dashwood RH, Uyetake L, Fong AT, Hendricks JD, and Bailey GS (1989) In vivo disposition of the natural anti-carcinogen indole-3-carbinol after po administration to rainbow trout. Food Chem Toxicol 27:385-392.
15. De Kruif CA, Marsman JW, Venekamp JC, Falke HE, Noordhoek J, Blaauboer BJ, and Wortelboer HM (1991) Structure elucidation of acid reaction products of indole-3-carbinol: detection in vivo and enzyme induction in vitro. Chem-Biol Interact 80:303-315.
16. Ge X, Yannai S, Rennert G, Gruener N, and Fares FA (1996) 3,3′-Diindolylmethane induces apoptosis in human cancer cells. Biochem Biophys Res Commun 228:153-158.
17. Gibaldi M and Perrier D (1982) Pharmacokinetics. Marcel Dekker, Inc., New York.
18. Grose KR and Bjeldanes LF (1992) Oligomerization of indole-3-carbinol in aqueous acid. Chem Res Toxicol 5:188-193.
19. Grubbs CJ, Steele VE, Casebolt T, Juliana MM, Eto I, Whitaker LM, Dragnev KH, Kelloff GJ, and Lubet RL (1995) Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res 15:709-716.
20. Hong CB, Kim HA, Firestone GL, and Bjeldanes LF (2002) 3,3′-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis (Oxf) 23:1297-1305.
21. Jacobs IC and Zeligs MA (1999) Facilitated absorption of a hydrophobic dietary ingredient. Proc Int Symp Control Rel Bfoact Mater 26:958-959.
22. Jacobs IC and Zeligs MA (2000) New formulation strategies for bioavailability enhancement of two poorly absorbed phytonutrient supplements: diindolylmethane and yohimbine bark extract. Proc Int Symp Control Rel Bioact Mater 27:1324-1325.
23. Jellinck PH, Forkert PG, Riddick DS, Okey AB, Michnovicz JJ, and Bradlow HL (1993) Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem Pharmacol 45:1129-1136.
24. Leibelt DA, Hedstrom OR, Fischer KA, Pereira CB, and Williams D (2003) Evaluation of chronic dietary exposure to indole-3-carbinol and absorption enhanced 3,3′diindolylmethane in Sprague-Dawley rats. Toxicol Sci 74:10-21.
25. Leong H, Firestone GL, and Bjeldanes LF (2001) Cytostatic effects of 3,3′-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-alpha expression. Carcinogenesis (Oxf) 22:1809-1817.
26. Manson MM, Hudson EA, Ball HW, Barrett MC, Clark HL, Judah DJ, Verschoyle RD, and Neal GE (1998) Chemoprevention of aflatoxin B1-induced carcinogenesis by indole-3-carbinol in rat liver-predicting the outcome using early biomarkers. Carcinogenesis (Oxf) 19:1829-1836.
27. Michnovicz JJ and Bradlow HL (1991) Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr Cancer 16:59-66.
28. Nachshon-Kedmi M, Yannai S, Haj A, and Fares FA (2003) Indole-3-carbinol and 3,3′-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol 41:745-752.
29. Nestorov I (2003) Whole body pharmacokinetic models. Clin Pharmacokinet 42:883-908.
30. Park JY and Bjeldanes LF (1992) Organ-selective induction of cytochrome P-450-dependent activities by indole-3-carbinol-derived products: influence on covalent binding of benzo-[a]pyrene to hepatic and pulmonary DNA in the rat. Chem-Biol Interact 83:235-247.
31. Poulin P and Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies. I. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129-156.
32. Sepkovic DW, Bradlow HL, and Bell M (2001) Quantitative determination of 3,3′-diindolyl-methane in urine of individuals receiving indole-3-carbinol. Nutr Cancer 41:57-63.
33. Stauch TR and Gudmundsson O (2002) Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Delivery Rev 54:315-328.
34. Stresser DM, Bjeldanes LF, Bailey GS, and Williams DE (1995a) The anticarcinogen 3,3′-diindolylmethane is an inhibitor of cytochrome P-450. J Biochem Toxicol 10:191-201.
35. Stresser DM, Williams DE, Griffin DA, and Bailey GS (1995b) Mechanisms of tumor modulation by indole-3-carbinol. Disposition and excretion in male Fischer 344 rats. Drug Metab Dispos 23:965-975.
36. Wattenberg LW and Loub WD (1978) Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res 38:1410-1413.
37. Yuan F, Chen DZ, Liu K, Sepkovic DW, Bradlow HL, and Auborn K (1999) Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. Anticancer Res 19:1673-1680.
38. Zeligs MA and Jacobs IC (2000) inventors, Bioresponse L.L.C., assignee. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals. U.S. patent 6,086,915. 2000 Jul 11.
39. Zeligs MA, Sepkovic DW, Manrique C, Macsalka M, Williams DE, and Bradlow HL (2002) Absorption enhanced 3,3′-diindolylmethane: human use in HPV-related, benign and precancerous condition (Abstract). Proc Am Assoc Cancer Res 43:3198.